To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults

NCT ID: NCT06931327

Last Updated: 2025-06-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-29
• Study Completion Date: 2025-04-18

Brief Summary

To evaluate the safety and pharmacokinetic characteristics of AJU-C711 in healthy adults

Conditions

Hypercholesterolemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequence A

Period 1: Reference Drug, single dose Period 2: Test Drug, single dose

Group Type: EXPERIMENTAL

Test Drug

Intervention Type: DRUG

AJU-C711

Reference Drug

Intervention Type: DRUG

C711R

Sequence B

Period 1: Test Drug, single dose Period 2: Reference Drug, single dose

Group Type: EXPERIMENTAL

Test Drug

Intervention Type: DRUG

AJU-C711

Reference Drug

Intervention Type: DRUG

C711R

Interventions

Test Drug

AJU-C711

Intervention Type: DRUG

Reference Drug

C711R

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy adult volunteers aged ≥ 19-year-old

2. Weight ≥ 50kg (man) or 45kg (woman), with calculated body mass index(BMI) of 18 to 30 kg/m2

3. Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings

4. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serum, urine test) and 12-lead ECG results during screening tests

6. Those who agree to contraception during the participation of clinical trial 7. Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial

Exclusion Criteria

1. Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug

2. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days

3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study

4. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug

5. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass/week, Women - 14 glass/week (1 glass: Soju 50 mL, liquor: 30mL or Beer 250mL)

6. Those who has under

• Those who are hypersensitive to component of the Investigational product and have the medical history
• Those with active liver disease or persistent elevation of aminotransferase levels of unknown
• Those with severe hepatic impairment or biliary atresia and cholestasis
• Those taking cyclosporin
• Those with myopathy
• Those who has a disease history of diabetic mellitus, nephropathy, biliary obstruction, dihydropyridine sensitivity, angioedema
• Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption

7. Those who has a history of mental illness

8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons

9. Women who are pregnant or who may be pregnant and breastfeed

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

AJU Pharm Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Bumin Hospital, Seoul, Republic of South Korea

Seoul, , South Korea

Countries

South Korea

Other Identifiers

24PHL11501

Identifier Type: -

Identifier Source: org_study_id